Figure 7
From: FTY720 in resistant human epidermal growth factor receptor 2-positive breast cancer
Xenograft mouse model of HCC1954 cells showing the efficacy of FTY720 with or without trastuzumab. (a) Mice bearing HCC1954 xenografts were randomized into four treatment groups (n = 9 for each group) when tumor size reached 150–200 mm3. Mice were treated with PBS, trastuzumab, FTY720, or FTY720 plus trastuzumab. Xenografts were harvested 24 h after the last treatment. Each plot indicates the mean increase in tumor volume from the first day of treatment, whereas error bars indicate the standard error of the mean. Differences between the four groups were analyzed using ANOVA with mixed-effect model. Differences in control versus FTY720 and control versus FTY720 plus trastuzumab were statistically significant. P value: *P < 0.05 and **P < 0.01. (b) Tumor tissue sections were evaluated using TUNEL assays (green) and also counterstained with Hoechst 33,342 dye (blue, indicating nuclei). They were then examined using fluorescence microscopy. The top three tissue sections with the most abundant green signals in each group were presented. (c) Using the same tissue sections, cell membranes were outlined using HER2-antibody conjugating secondary antibody (red) and then examined using fluorescence microscopy. Bar, 100 μm. F plus T: FTY720 plus trastuzumab.
